WORMTUMORS · Worm power: Can helminths modify the development of colorectal cancer?
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2015-08-01 → 2018-07-31
- EU contribution
- €203,200
- Participants
- 2
- Scheme
- MSCA-IF-GF
Lines connect the coordinator with its partners.
Results in brief
Worm power: Can helminths modify the development of colorectal cancer?
Colorectal cancer (CRC) causes ~694,000 deaths a year and is the 3rd most prevalent cancer in the world. Currently, the incidence of CRC is predicted to increase significantly more in low- and middle-income countries (LMIC) than in high-income countries (HIC) by 2035. In LMIC, infectious disease, including helminth infection, contribute to a third of all cancer cases and 20% of cancer deaths. Helminth infection affects more than 1.5 billion people in LMIC and can protect against immune-mediated diseases, in fact, live infection or helminth products are being used within clinical trials as novel therapeutics to treat inflammatory bowel disease. As LMIC develop economically, exposure to dietary and lifestyle risk factors associated with cancer will collide with existing high rates of infection with pathogens such as helminths. In this scenario, the ability of helminths to subvert or suppress the immune system of the host may be detrimental to cancer development. Currently it is unknown how helminth modulation of immunity influences CRC. The overriding objective of this proposal therefore, is to determine how helminth exposure influences colorectal cancer development. We have found that helminth infection increases inflammation and tumor development in a mouse model of disease. Changes in diet to one rich in fatty acids consumed in HIC also increased disease. Diet change clashed with underlying helminth infection resulting in a very poor outcome in this model. Increases in colorectal cancer following helminth infection and diet change are reliant on live helminth infection and are regulated by IL-4Ra signalling. Increased tumour development is associated with a reduced anti-tumor response and the increased production of inflammatory lipid mediators in the colon, where administration of one mediator increased tumor formation in naive mice. We conclude that helminth infection and diet change exacerbate colorectal cancer through regulation of fatty acid metabolism and increased production of lipid inflammatory mediators.
Data: CORDIS, © European Union
Project objective
The incidence of cancer is significantly lower in developing areas such as Africa, than in the Western world. These developing regions have a high incidence of helminth infection, which can protect against immune-mediated diseases and are currently being successfully used within clinical trials as novel therapeutics to treat inflammatory bowel disease. As Africa develops, lifestyle and dietary changes will collide with the presence of chronic infectious disease, such as gastrointestinal helminths, increasing the risk of colorectal cancer. The intrinsic immune-suppressive nature of helminth infections is known to be detrimental to the generation of immune responses to other infections and vaccination, and may also impair anti-tumor responses in vivo. We have recently found that local exposure to helminth products can result in increased tumor cell growth and metastasis. Currently, it is unknown how helminth modulation of immunity influences colorectal cancer incidence and progression. This fellowship proposal will make use of an inflammation-associated and spontaneous model of colorectal cancer to test the impact of live helminth infection and exposure to helminth excretory/secretory products on tumor development. It will further dissect the impact of helminth exposure on the innate and adaptive anti-tumor immune response, using multi-colour flow cytometry and cell-specific knockout mice. Furthermore, rescue of an impact of helminth exposure on anti-tumor immunity will be attempted by in vivo cell transfer. This fellowship aims to increase our understanding of how helminth infection contributes to tumor development and may lead to the design of novel therapeutics to improve tumor immunity.
Original text from CORDIS.
Participants
- CARDIFF UNIVERSITY · CARDIFFCoordinatorUnited Kingdom
- UNIVERSITY OF CAPE TOWN · RondeboschSouth Africa
Links
- View on CORDIS
- DOI: 10.3030/657639
- https://arquivo.pt/wayback/20201229225357/https://www.cardiff.ac.uk/people/view/310949-smith-katherine
Data: CORDIS, © European Union
